Clinical trial
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage…
NCT00005023 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00005023 |
|---|---|
| Title | Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer |
| Official title | A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers |
| Lead sponsor | University of Washington, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Lung Cancer, Ovarian Cancer |
| Intervention type | Biological |
| Interventions | HER-2/neu peptide vaccine, sargramostim |
| Start date | Mar 1, 1999 |
| Primary completion | Jan 1, 2001 |
| Completion | Jan 1, 2001 |
| First posted | Apr 23, 2004 |
| Last update posted | Nov 30, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: